Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
31 results about "Tert gene" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
TERT (Telomerase Reverse Transcriptase) is a Protein Coding gene. Diseases associated with TERT include Dyskeratosis Congenita, Autosomal Dominant 2 and Pulmonary Fibrosis And/Or Bone Marrow Failure, Telomere-Related, 1. Among its related pathways are Human T-cell leukemia virus 1 infection and HIF-1-alpha transcription factor network.
CRISPR/Cas12a gene editing system and application thereof
InactiveCN109666684AAchieve mutationWork lessHydrolasesStable introduction of DNATert geneEukaryotic cell
The invention relates to a CRISPR / Cas12a gene editing system and application thereof. The invention comprehensively utilizes biochemical, molecular biology, cell biology and other methods to screen and identify novel LiCas12a protein with endonuclease activity from a plurality of different bacteria. Based on LiCas12a, a CRISPR / LiCas12a gene editing system with high editing efficiency and high specificity is established in eukaryotic cells and prokaryotic cells separately, and genetic manipulation such as knockout, insertion and point mutation of genes is achieved; a molecular mechanism that the mutation of a TERT gene promoter promotes the cell proliferation of bladder cancer and liver cancer is disclosed. The genetic editing system based on CRISPR-LiCas12a provides a more accurate and efficient gene editing method for research fields such as disease pathogenesis and metabolic engineering transformation.
Owner:BEIJING UNIV OF CHEM TECH
Induced malignant stem cells or pre-induction cancer stem cells capable of self-replication outside of an organism, production method for same, and practical application for same
Disclosed are inducible cancer stem cells which are capable of in vitro self-replication and which are useful in research into cancer treatment and cancer-related drug development. Also disclosed are a production method for the above cells, cancer cells induced from the above stem cells, and a practical application of the cells. The disclosed inducible cancer stem cells which are capable of in vitro self-replication are characterised by satisfying requirements (1) and (2): (1) expressing six genes (POU5F1 gene, NANOG gene, SOX2 gene, ZFP42 gene, LIN28 gene, and TERT gene) selected from among a specified gene group; (2) (a) having an abnormality which is either the modification of an endogenous cancer suppression gene, or (b) the up-regulation of an endogenous cancer related gene.
Owner:NAT CANCER CENT
Probe set for detecting breakage of TERT (Telomerase Reverse Transcriptase) gene, kit and application of probe set
ActiveCN107177677AQuick checkRapid detection of breaks in the TERT geneMicrobiological testing/measurementDNA/RNA fragmentationFluorescenceTert gene
The invention provides a probe set for detecting the breakage of a TERT (Telomerase Reverse Transcriptase) gene, a kit and application of the probe set to preparation a reagent or the kit for identifying a high-risk patient suffered from neuroblastoma. The probe set provided by the invention comprises clonal fragments RP11-325I22, RP11-768M3, RP11-1107M2 and RP11-260H6, wherein the RP11-325I22 and the RP11-768M3 are marked with fluorescent dyes of the same color; the RP11-1107M2 and the RP11-260H6 are marked with the fluorescent dyes of another color. The breakage of the TERT gene can be quickly, accurately and sensitively detected.
Owner:BEIJING CHILDRENS HOSPITAL AFFILIATED TO CAPITAL MEDICAL UNIV
TERT gene combination mutation site detection kit
ActiveCN104404128AReduce consumptionReduce workloadMicrobiological testing/measurementDNA/RNA fragmentationTert geneBioinformatics
The invention belongs to the field of molecular diagnosis and provides a TERT gene combination mutation site detection kit. The kit provided by the invention comprises a primer pair capable of respectively amplifying fragments containing TERT gene polymorphic sites RS34094720, RS61748181, RS121918661, RS121918662, RS121918663 and RS121918664 and a sequencing primer for sequencing amplification products. The invention also provides a method for non-diagnostic detection of TERT gene combination mutation sites by the use of the kit.
Owner:GUANGZHOU KINGMED DIAGNOSTICS CENT
Primer for detecting variation of benign and malignant related genes of thyroid nodules, kit and detection method
ActiveCN110241215AImprove accuracyHigh detection sensitivityMicrobiological testing/measurementDNA/RNA fragmentationBiologyEIF1AX gene
The invention discloses a primer for detecting variation of benign and malignant related genes of thyroid nodules, a kit and a detection method. According to the primer, the kit and the detection method, variation of 15 loci of the six genes and variation of the three fusion genes can be detected simultaneously, and the BRAF gene, the KRAS gene, the HRAS gene, the NRAS gene, the TERT gene, the EIF1AX gene, RET / PTC1 fusion, RET / PTC3 fusion and PAX8 / PPARgamma fusion are involved. Hotspot mutation and fusion variation of the genes are closely related to the benign and malignant thyroid nodules. Therefore, the primer, the kit and the detection method are used for detecting a sample of a patient and can assist doctors in benign and malignant identification of the thyroid nodules which cannot be clearly diagnosed in the cytology, the accuracy of identifying the benign and malignant thyroid nodules is improved, excessive medical treatment for the patient with the thyroid nodules is reduced, and the primer, the kit and the detection method have important practical significance and high economic benefit for saving medical resources of China.
Owner:润安医学科技(苏州)有限公司
TERT gene polymorphism detection kit through pyrosequencing method, and method thereof
InactiveCN102899403AQuick analysisAccurate analysisMicrobiological testing/measurementNucleotideTert gene
The present invention discloses a TERT gene polymorphism detection kit through a pyrosequencing method, and a method thereof. With the kit, TERT gene polymorphism can be detected, and specifically rs2736100 (G is more than T) single nucleotide polymorphism is detected. The kit comprises primers represented by SEQ ID NO.2-4. According to the kit, accurate, fast and high-throughput detection can be performed on the TERT gene polymorphism so as to achieve effective prediction and prevention of susceptibility risk of lung cancer.
Owner:CENT SOUTH UNIV
Kit for detecting mutation of TERT gene promoter and detection method and application thereof
InactiveCN106148516ASimple reaction systemLow priceMicrobiological testing/measurementBladder cancerFluorescence
The invention belongs to the technology of clinical medicine gene detection and particularly relates to a kit for detecting mutation of a TERT gene promoter and a detection method and application thereof. The kit comprises a fluorescence labeling probe specifically recognizing mutation of a lotus C228T and mutation of a lotus C250T or other combinations of the TERT gene promoter, a pair of TERT specific primers and needed Master mix of all reagents. The specificity mutation C228T and the specificity mutation C250T of the TERT gene promoter are provided, and the sum of the specificity mutation C228T and the specificity mutation C250T accounts for about 100% of bladder cancer TERT mutation; a detection method is standardized, the reagents are subjected to optimization verification, the price is low, all ingredients in a reaction system are premixed, the operation process is simplified to the maximum extent, and operation errors are avoided. When the kit is used for detecting mutation of the TERT gene promoter, the number of influence factors is small, detection is precise, operation is easy, detection results are understood easily, and a reliable method for quickly detecting bladder cancer through urine is provided for clinical medicine.
Owner:上海汇真生物科技有限公司
Method and primer as well as kit for detecting mutation sites of promoters C250T and C228T of TERT (Telomerase Reverse Transcriptase) gene
InactiveCN105695596AImprove amplification specificityHigh sensitivityMicrobiological testing/measurementDNA/RNA fragmentationSanger sequencingTelomerase reverse transcriptase
The invention discloses a method, a primer and a kit for detecting mutation sites of promoters C228T and C250T of a telomerase reverse transcriptase (TERT) gene. The primer comprises a forward primer and a reverse primer for amplifying the mutation sites of the promoters C228T and C250T of the TERT gene, and in addition, can also comprise one pair of sequencing primers. A Touch-down PCR (Polymerase Chain Reaction) amplification technique is combined with a Sanger sequencing method; the occurrence conditions of the mutation sites of the promoters C228T and C250T of the TERT gene in a body of a patient suffered from a brain glioma can be quickly detected.
Owner:南京艾迪康医学检验所有限公司
Mitochondrion-targeted gene editing complex, preparation method and application thereof and mitochondrion genome editing method
ActiveCN112251468AHigh genetic heterogeneityImprove antioxidant capacityHydrolasesPeptide/protein ingredientsDouble strandTarget gene
The invention provides a mitochondrion-targeted gene editing complex, a preparation method and application thereof and a mitochondrion genome editing method. The gene editing complex comprises a mitochondria-targeted cationic liposome and an mtCRISPR / Cas9 system whihc are a mitochondrial TERT gene double-stranded homologous template, a crRNA of a specific targeting TERT, an RNA homologous recombination repair template and a Cas9 protein. A gene editing technology based on CRISPR / Cas9 is combined with a mitochondrial targeting means, the mitochondrion-targeted gene editing complex is provided,a normal mitochondrial TERT gene functional fragment is introduced to replace a mismatched gene, and the oxidative stress level is improved by up-regulating a mitochondrial TERT gene.
Owner:钟刚
Thyroid cancer auxiliary molecule diagnosis test kit and use method
InactiveCN111534599AImprove accuracyHigh detection sensitivityMicrobiological testing/measurementBraf genesTert gene
The invention provides a thyroid cancer auxiliary molecule diagnosis test kit. The thyroid cancer auxiliary molecule diagnosis test kit comprises amplification primers and probes for detecting BRAF, HRAS, KRAS, NRAS and TERT genes, internal control gene ACTB primers and probes, and external control gene BRAF primers and probes; the primers are specifically used for detecting a V600E site of the BRAF gene, a Q61R site of the HRAS gene, a G12C site of the KRAS gene, a G12D site of the KRAS gene, a G13R site of the KRAS gene, a G13D site of the KRAS gene, a Q61K site of the NRAS gene, a Q61P siteof the NRAS gene, a Q61H1 site of the NRAS gene, a Q61H2 site of the NRAS gene, a C228T site of the TERT gene and a C250T site of the TERT gene. The invention also provides a use method of the thyroid cancer auxiliary molecule diagnosis test kit. The problems of sensitivity, cost, operation convenience and the like of an existing thyroid cancer auxiliary molecule diagnosis test kit are solved.
Owner:重庆浦洛通基因医学研究院有限公司
A kind of primer and kit for detecting benign and malignant thyroid nodule related gene variation
ActiveCN110241215BImprove accuracyHigh detection sensitivityMicrobiological testing/measurementDNA/RNA fragmentationOncologyMalignancy
The invention discloses a primer for detecting variation of benign and malignant related genes of thyroid nodules, a kit and a detection method. According to the primer, the kit and the detection method, variation of 15 loci of the six genes and variation of the three fusion genes can be detected simultaneously, and the BRAF gene, the KRAS gene, the HRAS gene, the NRAS gene, the TERT gene, the EIF1AX gene, RET / PTC1 fusion, RET / PTC3 fusion and PAX8 / PPARgamma fusion are involved. Hotspot mutation and fusion variation of the genes are closely related to the benign and malignant thyroid nodules. Therefore, the primer, the kit and the detection method are used for detecting a sample of a patient and can assist doctors in benign and malignant identification of the thyroid nodules which cannot be clearly diagnosed in the cytology, the accuracy of identifying the benign and malignant thyroid nodules is improved, excessive medical treatment for the patient with the thyroid nodules is reduced, and the primer, the kit and the detection method have important practical significance and high economic benefit for saving medical resources of China.
Owner:润安医学科技(苏州)有限公司
SgRNA (small guide Ribonucleic Acid) for specifically identifying swine Tert (Telomerase Reverse Transcriptase) locus and encoding DNA (Deoxyribonucleic Acid) and application thereof
ActiveCN109679958AAchieve knockoutStrong specificityTransferasesFermentationEnrichment methodsLarge fragment
The invention provides sgRNA (small guide Ribonucleic Acid) for specifically identifying a swine Tert (Telomerase Reverse Transcriptase) locus. The sgRNA is formed by pTert-exon1-sgRNA and pTert-exon2-sgRNA, wherein a nucleotide sequence which is responsible for target fragments in the pTert-exon1-sgRNA is SEQ ID NO.1; a nucleotide sequence which is responsible for target fragments in the pTert-exon2-sgRNA is SEQ ID NO.2. The sgRNA for the swine Tert locus is strong in specificity. The sgRNA for the swine Tert locus can utilize CRISPR / Cas9 gene editing system and a bifluorescence enrichment method and is capable of efficiently realizing large-fragment knockout of the swine Tert gene, the homozygote efficiency can be up to 50 percent, and preliminary technical support is provided for follow-up research on swine Tert gene functions.
Owner:FOSHAN UNIVERSITY
Multiple PCR (Polymerase Chain Reaction) primer composition, reagent and multiple PCR-breaking control system for TERT (Telomerase Reverse Transcriptase) gene whole exome next-generation sequencing
PendingCN111763731AWhole exome next-generation sequencing implementationComprehensive detectionMicrobiological testing/measurementDNA/RNA fragmentationBraf genesMedicine
The invention provides a multiple PCR (Polymerase Chain Reaction) primer composition, a reagent and a multiple PCR-breaking control system used for TERT (Telomerase Reverse Transcriptase) gene whole exome next-generation sequencing. The multiple PCR primer composition used for the TERT gene whole exome next-generation sequencing comprises primers disclosed from SEQ ID NO: 01 to SEQ ID NO: 32. Themultiple PCR primer composition, the reagent and the multiple PCR-breaking control system for the TERT gene whole exome next-generation sequencing solves the following existing technical problems that1: since the point mutation of the BRAF gene is mainly detected in the prior art, a detection range is limited; 2: real-time fluorescent quantitation PCR (Polymerase Chain Reaction) detection and a gene chip only can detect known sites; 3: a Sanger sequencing checkout length is smaller than a range of 800 bp; 4: low-frequency mutation can not be detected; and 5: when a plurality of sites are detected, operation is complex, and cost is high.
Owner:CHANGSHA KINGMED MEDICAL DIAGNOSTICS INST
Combined marker for early diagnosis of liver cancer and application of combined marker.
ActiveCN113337608AIncreased sensitivityWill not cause disseminationMicrobiological testing/measurementDNA/RNA fragmentationAXIN1SEMA4D
The invention discloses a combined marker for early diagnosis of liver cancer and an application of the combined marker. The combined marker for early diagnosis of the liver cancer disclosed by the invention is methylation of FAM78A, MKL1, DCDC2, SR, BCL2L11, CYP1B1, PTPN7, AXIN1, SEMA4D, PROX1, SHH, AK055957, DAB2IP, TBX15, GRASP, PPFIA1 and / or PSD4, and mutation of TERT and / or CTNNB1. According to the invention, liver cancer detection is realized by detecting the methylation level of gene combination in plasma cfDNA, and the combined marker has high sensitivity and specificity; Under the condition of mutation detection after adding genes, the early screening sensitivity is effectively improved by detecting methylation of a gene combination and mutation of TERT genes and CTNNB1 genes at the same time.
Owner:CANCER INST & HOSPITAL CHINESE ACADEMY OF MEDICAL SCI +1
Biomarker for thyroid nodule benign and malignant discrimination, multi-gene joint detection kit and application
PendingCN114807350AHigh sensitivitySimple and fast operationMicrobiological testing/measurementDNA/RNA fragmentationBase JBiomarker (medicine)
The invention belongs to the field of biological medicine, and discloses a biomarker for judging benign and malignant thyroid nodules, a multi-gene joint detection kit and application. The biomarker group comprises at least one of eight DNA single base mutations and four gene fusions; the eight kinds of DNA single base mutations are selected from a BRAF gene V600E, a TERT gene C228T / C250T, a KRAS gene G12C / G12V / Q61R, an NRAS gene Q61R and an HRAS gene Q61R, and the four kinds of gene fusion are selected from CCDC6-RET (Exon1-Exon12), NCOA4-RET (Exon8-Exon12), PAX8-PPARG (Exon10-Exon2) and ETV6-NTRK3 (Exon4-Exon14). The method and the kit are high in detection sensitivity, high in specificity and wide in application scene.
Owner:上海睿璟生物科技有限公司
Insulin-secreting immortalized liver cell line modified by glucose sensitivity
The present invention provides a cell line which can be substituted for β cells in human mature pancreatic islets and express insulin in a glucose-concentration dependent manner, and enables the easy obtainment of the number of cells which meets the demand. The present invention also provides a therapeutical cell preparation for treating diabetes. The cell lines of the present invention can be obtained by integrating both a nucleotide sequence encoding tamoxifen-induced Cre recombinase and a nucleotide sequence encoding insulin regulated by glucose-sensitive promoter into the chromosome in a human immortalized hepatic cell line FERM BP-7498 containing the TERT gene inserted in between a pair of LoxP sequences.
Owner:KOBAYASHI NAOYA +5
MicroRNA328 for regulating expression of TERT gene and application of microRNA328
ActiveCN110623975AHigh activityEnhanced inhibitory effectOrganic active ingredientsNervous disorderTelomeraseDisease
The present invention discloses a microRNA328 for regulating expression of TERT gene and an application of the microRNA328, and provides uses of the microRNA328 or a substance inhibiting expression ofthe microRNA328. The miR328 is found to have a significant inhibitory effect on an expression level of TERT mRNA in Hela cells and an oligonucleotide inhibitor of the miR-328 has a significant up-regulation effect on the expression level of the TERT gene mRNA in the Hela cells. The inhibitor of the miR-328 significantly increases angiogenic capacity of EPC. The EPC transfected by the inhibitor ofthe miR-328 significantly inhibits differentiation of NSCs into glial cells. Studies show that using miRNAs as targets or tools to enhance telomerase activity provide theoretical basis for treatmentof neurological diseases of vascular dementia (VD), etc. and have potential clinical application value.
Owner:XINXIANG MEDICAL UNIV
Application of SNP (single nucleotide polymorphism) in field of breast cancer chemotherapy drug resistance detection and detection kit of breast cancer chemotherapy drug resistance
ActiveCN112553336AIncreased sensitivityImprove stabilityMicrobiological testing/measurementAgainst vector-borne diseasesMedicineTert gene
The invention discloses an application of SNP (single nucleotide polymorphism) in the field of breast cancer chemotherapy drug resistance detection and a detection kit of breast cancer chemotherapy drug resistance, and belongs to the technical field of biological medicine. The SNP is an SNP locus rs9344 of a CCND1 gene and / or an SNP locus rs33954691 of a TERT gene. The detection kit of breast cancer chemotherapy drug resistance comprises a primer pair for detecting an SNP locus rs9344 of a CCND1 gene and / or an SNP locus rs33954691 of a TERT gene, and five primers for detecting the SNP locus rs9344 of the CCND1 gene are shown as SEQ ID NO.1-SEQ ID NO.5, five primers for detecting the SNP locus rs33954691 of the TERT are shown as SEQ ID NO.6-SEQ ID NO.10. The correlation of the rs9344 locuson the CCND1 gene and the rs33954691 locus on the TERT gene with breast cancer chemotherapy drug resistance is discovered for the first time, drug resistance screening is carried out during breast cancer chemotherapy, and the effects of risk early warning and early estimation can be effectively achieved.
Owner:LANZHOU UNIVERSITY
Methods for extending the replicative capacity of somatic cells during an ex vivo cultivation process
PendingUS20220251550A1Improve proliferative abilityIncrease capacityHydrolasesGenetically modified cellsBiotechnologyExon
Owner:UPSIDE FOODS INC
Kit for evaluating effect of 131I on treating differentiated thyroid cancer
InactiveCN112646894AStrong combination specificityAvoid mutual interferenceMicrobiological testing/measurementDNA/RNA fragmentationTreatment effectBraf genes
The invention discloses a primer and kit for evaluating the effect of 131I on treating differentiated thyroid cancer. The kit can be used for simultaneously detecting the variation of nine gene loci of a BRAF gene, a TERT gene, an HRAS gene and an NRAS gene, and the variation of the gene loci is closely related to the treatment effect of 131I on differentiated thyroid cancer. Therefore, when the kit is used for detecting a sample of a patient, a doctor can be assisted in scientifically evaluating the clinical effect of treating a differentiated thyroid cancer patient by using 131I, a basis is provided for making a precise treatment scheme of the patient, and the kit undoubtedly has very important clinical use value.
Owner:润安医学科技(苏州)有限公司
Multiplex PCR primer composition, reagent and control system for next-generation sequencing of whole exons of TERT gene
PendingCN111763719ARealize whole exome next generation sequencingComprehensive detectionBioreactor/fermenter combinationsBiological substance pretreatmentsMultiplexControl system
The invention provides a multiplex PCR primer composition, a reagent and a control system for next-generation sequencing of whole exons of TERT gene. The multiplex PCR primer composition for the second-generation sequencing of the whole exons of the TERT gene comprises primers shown as SEQ ID NO: 01 to SEQ ID NO: 50. The multiplex PCR primer composition, the reagent and the control system for thesecond-generation sequencing of the whole exons of the TERT gene provided by the invention solve the following existing technical problems: 1, the point mutation of a TERT gene promoter is mainly detected in the prior art, and the detection range is limited; 2, real-time fluorescent quantitative PCR detection is carried out, and the gene chip can only detect known sites; 3, the Sanger sequencing test length is in the range of less than 800bp; 4, when multiple sites are detected, the operation is tedious, and the cost is high; and 5, low-frequency mutation cannot be detected.
Owner:CHANGSHA KINGMED MEDICAL DIAGNOSTICS INST
MicroRNA328 regulating tert gene expression and its applications
ActiveCN110623975BHigh activityEnhanced inhibitory effectOrganic active ingredientsNervous disorderTelomeraseNeuroglia differentiation
The invention discloses microRNA328 regulating TERT gene expression and its application. The present invention provides the use of microRNA328 or a substance that inhibits its expression. The present invention finds that miR328 has a significant inhibitory effect on the expression level of TERT mRNA in Hela cells, and an oligonucleotide inhibitor of miR-328 has a significant up-regulation effect on the expression level of TERT gene mRNA in Hela cells. The inhibitor of miR-328 significantly increased the angiogenic capacity of EPCs. EPCs transfected with the inhibitor of miR-328 significantly inhibited the differentiation of NSCs into glial cells. Studies have shown that using miRNA as a target or tool to enhance the activity of telomerase provides a theoretical basis for the treatment of neurological diseases such as vascular dementia (VD), and has potential clinical application value.
Owner:XINXIANG MEDICAL UNIV
Combined marker for early diagnosis of liver cancer and its application
ActiveCN113337608BIncreased sensitivityWill not cause disseminationMicrobiological testing/measurementDNA/RNA fragmentationGenes mutationAXIN1
The invention discloses a combined marker for early diagnosis of liver cancer and its application. The combined markers for early diagnosis of liver cancer disclosed in the present invention are FAM78A, MKL1, DCDC2, SR, BCL2L11, CYP1B1, PTPN7, AXIN1, SEMA4D, PROX1, SHH, AK055957, DAB2IP, TBX15, GRASP, PPFIA1 and / or PSD4. Methylation, and mutation of TERT and / or CTNNB1. The present invention performs liver cancer detection by detecting the methylation level of the gene combination in the plasma cfDNA, and has high sensitivity and specificity; in the case of adding the mutation detection of the gene, by simultaneously detecting the methylation of the gene combination and the TERT gene , CTNNB1 gene mutation, effectively improve the sensitivity of early screening.
Owner:CANCER INST & HOSPITAL CHINESE ACADEMY OF MEDICAL SCI +1
Method for detecting hotspot mutation of human TERT gene promoter
InactiveCN111424094AImprove accuracyImprove featuresMicrobiological testing/measurementGeneQuantTert gene
The invention discloses a method for detecting hot spot mutation of a human TERT gene promoter. The method comprises the following steps: a, enriching templates by adopting DNA enrichment conventionalPCR aiming at different specimens; b, purifying the PCR product, determining the concentration by using an ultraviolet spectrophotometer, and performing concentration calibration and standard substance preparation; and c, carrying out TERT-146 (C / T) and TERT-124 (C / T) mutation rate quantitative detection on the calibrated specimens by adopting qPCR. According to the method, a qPCR technology platform which is conventionally developed clinically is adopted, the high-sensitivity TERT hot spot mutation rate quantitative detection method is established for DNA specimens from various sources, thelower limit of the detected mutation rate reaches 0.05%, and the method has the advantages of being high in detection sensitivity, high in specificity, capable of accurately and quantitatively detecting the mutation rate, low in cost, suitable for conventional clinical development and the like.
Owner:AEROSPACE CENT HOSPITAL
The sgRNA that specifically recognizes the porcine tert site, its coding DNA and its application
The present disclosure provides sgRNA that specifically recognizes the pig Tert site, wherein the sgRNA is composed of pTert-exon1-sgRNA and pTert-exon2-sgRNA, and the nucleotide sequence responsible for recognizing the target fragment in the pTert-exon1-sgRNA is SEQ ID NO:1; the nucleotide sequence responsible for recognizing the target fragment in the pTert-exon2-sgRNA is SEQ ID NO:2. The sgRNA at the pig Tert site has strong specificity. The sgRNA at the pig Tert site can use the CRISPR / Cas9 gene editing system and the double fluorescence enrichment method, which can efficiently knock out large fragments of the pig Tert gene, and the homozygous efficiency can reach 50%. Functional research provided preliminary technical support.
Owner:FOSHAN UNIVERSITY
A primer and kit for detecting gene variation related to prognosis of thyroid cancer
ActiveCN111748628BGood treatment effectImprove the quality of lifeMicrobiological testing/measurementDNA/RNA fragmentationRet geneTherapeutic effect
The invention provides a primer and a kit for detecting the variation of genes related to the prognosis of thyroid cancer. Based on high-throughput sequencing technology, this method can quickly, comprehensively and accurately detect BRAF gene T1799A, A1801G mutation, TERT gene C228T, C250T mutation, RET gene T2753C mutation, EIF1AX gene G25C / A / T, G370T, G371T mutation and TP53 Gene G818A mutation. The above-mentioned mutations of these genes are closely related to the prognosis of thyroid cancer. Therefore, using the present invention to detect patient samples can assist doctors in evaluating and judging the prognosis of thyroid cancer patients, and provide valuable decision-making basis and guidance for doctors to choose appropriate surgical methods and formulate postoperative follow-up plans in a targeted manner. Reference information is helpful to improve the treatment effect and quality of life of patients with thyroid cancer, and has very important clinical value.
Owner:润安医学科技(苏州)有限公司
TERT mutation detection kit and application thereof in noninvasive tumor diagnosis
InactiveCN111560436ARealize non-invasive sampling detectionRelieve painMicrobiological testing/measurementDNA/RNA fragmentationMelanomaTert promoter
The invention particularly relates to a TERT mutation detection kit and an application of the TERT mutation detection kit in non-invasive tumor diagnosis. The invention provides a primer combination,a kit, a method and an application (ddPCR-TERTpm kit) for detecting TERT gene promoter mutation based on a ddPCR method, and aims to solve the problems of complex detection and low sensitivity in theprior art. The ddPCR-TERTpm kit is suitable for detection of tumor and urine mutation TERT promoters of bladder and renal pelvis cancer patients. After urine DNA is extracted, ddPCR amplification analysis is carried out, and the kit has the advantages of rapidness, simplicity, convenience, high sensitivity, specificity and the like. In addition, the detection kit or technology is also suitable fordetection of malignant melanoma, brain glioma, hepatocellular carcinoma and other tumors and blood specimens, and molecular diagnosis of thyroid tumors and DNA derived from fine needle puncture specimens.
Owner:郑成云
miRNA138 and application of miRNA138 in regulation of TERT gene expression
PendingCN110724688AHas clinical application valueInhibition of differentiationOrganic active ingredientsNervous disorderTert geneBiochemistry
The invention discloses miRNA138 and an application of the miRNA138 in regulation of TERT gene expression. The invention provides miRNA138 and an application of an inhibitor of the miRNA138. The invention finds that the miR138 has a remarkable inhibition effect on the expression level of TERT mRNA of Hela cells, an oligonucleotide inhibitor of the miR-138 has a remarkable up-regulation effect on the mRNA expression level of the TERT gene of the Hela cell, the inhibitor of the miR-138 has the advantages that the blood vessel forming capability of the EPC is obviously improved, according to theinfluence of the miR-138 inhibitor on the differentiation of the EPC co-cultured NSC, the EPC transfected by the inhibitor of the miR-138 obviously inhibits the differentiation of the NSC to the glialcells.
Owner:XINXIANG MEDICAL UNIV
Method and kit used for determining human TERT gene rs2735940 site polymorphism
InactiveCN105256005AReduce yieldControl characteristicsMicrobiological testing/measurementHuman DNA sequencingEnzyme digestion
Owner:ZHENGZHOU UNIV
Kit for detecting hot spot mutation of human TERT gene promoter
PendingCN110724742AWide range of clinical applicationsImprove accuracyMicrobiological testing/measurementMedicineWild type
The invention discloses a kit for detecting hot spot mutation of a human TERT gene promoter. The method is characterized in that the kit is characterized by comprising a DNA enrichment conventional PCR premixing reagent for detecting mutation sites of TERT gene promoters-124 (C / T) and-146 (C / T), -124 (C / T) and-146 (C / T) mutant plasmids, a human peripheral blood wild type DNA standard substance, and -124 (C / T) and-146 (C / T) mutation rate detection qPCR premix reagents. The kit provided by the invention adopts a fluorescent quantitative PCR technology platform which is conventionally developed clinically, is used for detecting DNA specimens from various sources, and has the characteristics of high detection sensitivity, strong specificity, accurate quantitative detection of mutation rate, low cost, suitability for conventionally developing clinically and the like.
Owner:AEROSPACE CENT HOSPITAL
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com